Effect of angiotensin receptor blockade on systemic right ventricular function and size: A small, randomized, placebo-controlled study

Therrien, Judith; Provost, Yves; Harrison, Jeanine; Connelly, Michael S.; Kaemmerer, Harald; Webb, G. D.

doi:10.1016/j.ijcard.2008.04.056

Cited by 95 publications

(56 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of studies on the effects of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and β-blockers have been mixed; some have demonstrated a significant improvement and others have not. [19][20][21][22][23][24][25][26][27] Our data on the poor response to CRT pacing for sRV patients are analogous to the effect of medical treatments for congestive heart failure in sRV patients. We do not yet know the pacing sites that are optimal for a systemic RV.…”

Section: Acute Hemodynamic Studymentioning

confidence: 95%

Cardiac Resynchronization Therapy for Various Systemic Ventricular Morphologies in Patients With Congenital Heart Disease

Sakaguchi

Miyazaki

Yamada

et al. 2015

Circ J

View full text Add to dashboard Cite

Section: Acute Hemodynamic Studymentioning

confidence: 95%

Cardiac Resynchronization Therapy for Various Systemic Ventricular Morphologies in Patients With Congenital Heart Disease

Sakaguchi

Miyazaki

Yamada

et al. 2015

Circ J

View full text Add to dashboard Cite

“…Although there are no randomized control trials in this patient population, evidence based therapies in heart failure with reduced ejection fraction have been applied, which include angiotensin converting enzyme inhibitor or angiotensin II receptor blocker and beta-blocker therapies [14][15][16][17][18][19]. There is no evidence for digoxin; however, it can be used.…”

Section: Medical and Device Therapymentioning

confidence: 99%

Ventricular Assist Devices in Patients with Systemic Right Ventricular Failure due to Congenitally Corrected Transposition of the Great Arteries

Sehgal¹,

Ahluwalia²

2017

J Clin Exp Cardiolog

View full text Add to dashboard Cite

Congenitally corrected transposition of the great arteries is increasingly recognized as an adult congenital heart problem. Although early atrial switch surgical repairs resulted in improved overall survival, these patients are further predisposed to systemic ventricular failure in their fourth and fifth decades of life. Early diagnosis and management of systemic ventricular dysfunction are often challenging. Ventricular assist devices may become a mainstay endstage treatment option for these patients as a destination therapy or a bridge to heart transplantation.

show abstract

“…(17)(18)(19) Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have previously been shown to decrease myocardial fibrosis and attenuate ventricular remodelling with a resultant increase in myocardial function and decrease in mortality in patients with both asymptomatic and symptomatic left ventricular dysfunction. (20)(21)(22)(23) There have been several small trials using ACEIs and ARBs in patients with a systemic RV but results have been disappointing.…”

Section: Spring 2013mentioning

confidence: 99%

“…(20)(21)(22)(23) There have been several small trials using ACEIs and ARBs in patients with a systemic RV but results have been disappointing. (17,24,25) A recent placebo-controlled study from the Netherlands studied the effect of the ARB valsartan on patients with either a previous atrial repair for TGA or cTGA. (26) Eighty eight patients were enrolled, 44…”

Section: Spring 2013mentioning

confidence: 99%

Management of advanced adult congenital heart disease

Bowater

2017

SAHJ

View full text Add to dashboard Cite

As surgical techniques continue to develop, for example as seen with the Norwood procedure for hypoplastic left heart syndrome, the number of patients with the most complex forms of CHD will continue to increase along with their associated long term complications. Our ability to manage these patients appropriately, therefore, must also develop alongside. The purpose of this review is to examine the management of these patients once they have developed advanced disease, including drug therapy, devices, transplant and end of life care. In particular, the unique problems posed by patients with a systemic right ventricle (RV) and univentricular circulations are discussed. DRUG THERAPY IN HEART FAILUREIn patients with complex congenital heart disease, either palliated or unoperated, the development of ventricular dysfunction and clinical heart failure are common and as discussed above, is a common cause of morbidity and mortality in this population.

show abstract

Effect of angiotensin receptor blockade on systemic right ventricular function and size: A small, randomized, placebo-controlled study

Cited by 95 publications

References 29 publications

Cardiac Resynchronization Therapy for Various Systemic Ventricular Morphologies in Patients With Congenital Heart Disease

Cardiac Resynchronization Therapy for Various Systemic Ventricular Morphologies in Patients With Congenital Heart Disease

Ventricular Assist Devices in Patients with Systemic Right Ventricular Failure due to Congenitally Corrected Transposition of the Great Arteries

Management of advanced adult congenital heart disease

Contact Info

Product

Resources

About